

Fluoroquinolone-
Associated
Disability (FQAD) -
Pathogenesis,
Diagnostics,
Therapy and
Diagnostic Criteria

Side-effects of Fluoroquinolones

Stefan Pieper

 Springer

Fluoroquinolone-Associated Disability (FQAD) - Pathogenesis, Diagnostics, Therapy and Diagnostic Criteria

Stefan Pieper

Fluoroquinolone- Associated Disability (FQAD) - Pathogenesis, Diagnostics, Therapy and Diagnostic Criteria

Side-effects of Fluoroquinolones

 Springer

Stefan Pieper
Konstanz
Baden-Württemberg
Germany

ISBN 978-3-030-74172-3 ISBN 978-3-030-74173-0 (eBook)
<https://doi.org/10.1007/978-3-030-74173-0>

Translation from the language edition: Fluoroquinolone-Associated Disability FQAD: Pathogenese, Diagnostik, Therapie und Diagnosekriterien by Stefan Pieper, © Springer Fachmedien Wiesbaden GmbH, ein Teil von Springer Nature 2020. Published by Springer Fachmedien Wiesbaden. All Rights Reserved.

© The Editor(s) (if applicable) and The Author(s), under exclusive license to Springer Nature Switzerland AG 2021

This work is subject to copyright. All rights are solely and exclusively licensed by the Publisher, whether the whole or part of the material is concerned, specifically the rights of reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed.

The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

The publisher, the authors, and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, expressed or implied, with respect to the material contained herein or for any errors or omissions that may have been made. The publisher remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This Springer imprint is published by the registered company Springer Nature Switzerland AG

The registered company address is: Gewerbestrasse 11, 6330 Cham, Switzerland

Preface

The term ‘Fluoroquinolone-Associated Disability’, FQAD, has been an established entity at least since its use by the FDA at the Joint Meeting of the Antimicrobial Drugs Advisory Committee and the Drug Safety and Risk Management Advisory Committee, November 5, 2015 [1].

(However, others played a decisive role in its creation, above all Charles Bennett, University of South Carolina, Beatrice Alexandra Golomb and Jay Cohen, University of California, Krzysztof Michalak, University in Poznań, Poland, without whose fundamental work [2] this book would not have been possible, and Miriam J. van Staveren de Jonge, physician and patient, as well as Lisa Bloomquist with FloxieHope, David Melvin with MyQuin-Story and numerous patients organized in self-help groups and forums, e.g. the fluorquinolone-forum.de.)

However, the FDA’s definition with the associated diagnostic criteria is not suitable for the treating physician in everyday use [3].

This vade mecum is supposed to help the doctor and/or therapist to deal better and more adequately with affected patients and perhaps also be a guideline for the ‘floxies’ themselves.

At the beginning, the four major ‘construction sites’, which are caused as adverse effects of the fluoroquinolones and can lead to FQAD, are each discussed in compact form.

Special attention is paid to the pathogenesis, diagnostics and the limited therapeutic options which, from my point of view, may have a chance of success.

In the second part, I would like to propose diagnostic criteria for FQAD that achieve the most reliable and likewise time-saving containment of the new clinical picture and thus to attempt implementing them in everyday practice.

This book is also intended to pass on my experiences that I have made in our practice in recent years with about 500 FQAD patients, whose feedback has provided valuable suggestions for better understanding and treatment of this new disease.

Konstanz, Germany

Stefan Pieper

References

1. FDA's Adverse Event Reporting System (FAERS). Review: "Fluoroquinolone-Associated Disability" (FQAD). 2015.
2. Michalak K, et al. Treatment of the fluoroquinolone-associated disability: the pathobiochemical implications. *Oxid Med Cell Longev*. 2017;2017:8023935. <https://doi.org/10.1155/2017/8023935>.
3. FDA/CDER Drug Information Webinar. "Fluoroquinolone-Associated Disability" (FQAD). April 4, 2017.

Acknowledgement

I would like to thank my dear wife and colleague Dr. Nicola Pieper for her constant commitment in the background, for her suggestions and caring support.

Contents

1	Introduction to FQAD	1
	References	6
2	FQAD and Oxidative Stress/Mitochondrial Toxicity	7
2.1	Pathogenesis	7
2.2	Diagnostics	9
2.3	Therapy	10
	References	14
3	FQAD and Musculoskeletal Damage/Collagen Disorder	17
3.1	Pathogenesis	18
3.2	Diagnostics	20
3.3	Therapy	20
3.4	Hydroxyproline	21
	References	22
4	FQAD and Neurotoxicity/Peripheral Neuropathy (PN)/Autonomic Neuropathy/Small Fibre Neuropathy	27
4.1	Pathogenesis	28
4.2	Diagnostics	28
4.3	Therapy	29
4.4	Small Fibre Neuropathy	30
	References	31